Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study.
Amino acids
Hip fractures
Myostatin
Nutrition therapy
Rehabilitation
Sarcopenia
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
06
11
2019
accepted:
28
11
2019
pubmed:
16
12
2019
medline:
14
8
2020
entrez:
16
12
2019
Statut:
ppublish
Résumé
Hip fractures are the most common osteoporotic fractures related to disability in older adults, requiring surgery and a subsequent rehabilitation treatment. Sarcopenia is currently considered as a predictive of worse outcome in hip fracture patients and myostatin has been recently proposed a potential biomarker of this condition. Twenty hip fracture patients after total hip replacement (mean aged 75.9 ± 2.4 years) were randomly divided into two groups of ten subjects (groups A and B). Both groups performed a rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol). Group A received also 2-month amino acid supplementation. Serum myostatin levels significantly decreased after 2 months in both group A (p = 0.01) and group B (p = 0.03) in sarcopenic patients only in group A (p = 0.04). These results suggest that myostatin might be considered a promising biomarker of sarcopenia in hip fracture older adults' patients undergoing rehabilitation and amino acid supplementation.
Identifiants
pubmed: 31838642
doi: 10.1007/s40520-019-01436-8
pii: 10.1007/s40520-019-01436-8
doi:
Substances chimiques
Biomarkers
0
MSTN protein, human
0
Myostatin
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
959-962Références
Calvani R, Picca A, Marini F et al (2018) The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study: rationale, design and methods. Eur J Intern Med 56:19–25
doi: 10.1016/j.ejim.2018.05.001
Tarantino U, Capone A, Planta M et al (2010) The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study. Arthritis Res Ther 12:R226
doi: 10.1186/ar3213
Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31
doi: 10.1093/ageing/afy169
White TA, LeBrasseur NK (2014) Myostatin and sarcopenia: opportunities and challenges—a mini-review. Gerontology 60:289–293
doi: 10.1159/000356740
Cho TJ, Gerstenfeld LC, Einhorn TA (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17:513–520
doi: 10.1359/jbmr.2002.17.3.513
Guo W, Flanagan J, Jasuja R et al (2008) The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem 283:9136–9145
doi: 10.1074/jbc.M708968200
de Souza EO, Tricoli V, Aoki MS et al (2014) Effects of concurrent strength and endurance training on genes related to myostatin signaling pathway and muscle fiber responses. J Strength Cond Res 28:3215–3223
doi: 10.1519/JSC.0000000000000525
Binns A, Gray M, Henson AC et al (2017) Changes in lean mass and serum myostatin with habitual protein intake and high-velocity resistance training. J Nutr Health Aging 21:1111–1117
doi: 10.1007/s12603-017-0883-6
Becker C, Becker C, Lord SR et al (2015) Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 3:948–957
doi: 10.1016/S2213-8587(15)00298-3
Paoli A, Pacelli QF, Neri M et al (2015) Protein supplementation increases postexercise plasma myostatin concentration after 8 weeks of resistance training in young physically active subjects. J Med Food 18:137–143
doi: 10.1089/jmf.2014.0004
Sukkar SG, Gallo F, Borrini C et al (2012) Effects of a new mixture of essential amino acids (Aminotrofic
doi: 10.3233/s12349-012-0098-7
Iolascon G, Moretti A, de Sire A et al (2018) Pharmacological therapy of sarcopenia: past, present and future. Clin Cases Miner Bone Metab 15:411–419
de Sire A, Invernizzi M, Lippi L et al (2019) Nutritional supplementation in hip fracture sarcopenic patients: a narrative review. Clin Cases Miner Bone Metab. 16:27–30
Invernizzi M, de Sire A, D’Andrea F et al (2019) Effects of essential amino acid supplementation and rehabilitation on functioning in hip fracture patients: a pilot randomized controlled trial. Aging Clin Exp Res 31:1517–1524
doi: 10.1007/s40520-018-1090-y
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423
doi: 10.1093/ageing/afq034